Roland Buelow, PhD

Board Member

Dr. Roland Buelow founded and was Chief Executive Officer of Ancora Biotech, where he currently serves as the Chairman of the Board. He is the former founder and Chief Executive Officer of Teneobio, a biotechnology company that developed a new class of biologics called Human Heavy-Chain Antibodies, which entered into several strategic partnerships – including AbbVie, AstraZeneca, Kite, and Janssen – before it was acquired by Amgen in 2021.

Roland was previously founder and Chief Executive Officer of Open Monoclonal Technology (OMT), which developed OmniRat, OmniFlic, Omnimouse, and UniRat, and was acquired by Ligand Pharmaceuticals in 2015. During his stewardship, OMT entered into license agreements with multiple leading biotechnology partners such as Amgen, Genmab, Janssen, Merck, Pfizer, and Seagen (formerly Seattle Genetics). He was also a founder of THP, a biotechnology company that engineered rabbits to produce human antibodies, that was acquired by Roche in 2007.

As a Fulbright scholar, Roland attended the University of Texas at Austin. He holds an MS in Biology from the Eberhard Karl University of Tübingen, and a PhD in Biology from the Max-Planck-Institute, Tübingen, Germany. He did his postdoctoral training at Stanford School of Medicine. Roland has published more than 100 manuscripts and is an inventor listed on more than 30 U.S. patents.